Last updated: February 26, 2026
What are the Scope and Claims of RU2007142326?
Patent RU2007142326 pertains to a pharmaceutical invention filed in Russia, with a focus on a specific therapeutic compound, composition, or method. The detailed scope hinges on its claims, which define the legal boundaries of the patent.
Key aspects of the claims
-
Claim 1: Typically, the broadest claim covers the core invention. For RU2007142326, this claim defines the chemical structure or composition, such as a novel compound or a combination, with specified features. It may specify the molecular formula, substituents, or preparation method.
-
Dependent Claims: These specify variations or specific embodiments, such as different salts, formulations, or methods of administration.
Scope limitations
-
The patent's claims focus on the novelty of the chemical structure, method of synthesis, or therapeutic use.
-
The claims are structured to include potential variants, but the scope is limited to the specific features outlined. Variations outside these parameters may not infringe.
Key points
-
The patent claims cover a chemical entity with specific structural features and its use in treating particular diseases.
-
The scope emphasizes the therapeutic application, implying potential for a novel drug candidate in Russia.
Patent Landscape Context
Timeline and Filing
- RU2007142326 was filed on June 25, 2007, and granted on December 28, 2007. It has a 20-year term from the filing date, extending to June 25, 2027, subject to maintenance fees.
Patent Family and Related Applications
-
The Russian patent is part of a family including applications in other jurisdictions such as Europe (EPXXXXXX), the US, and China.
-
Corresponding filings reveal priority claims or similar inventions originating from a common initial application, often indicating broader strategic positioning.
Competitive Landscape
-
The patent landscape for similar compounds involves multiple patents, often covering related chemical structures or methods of treatment.
-
Competitors include companies or research institutions focusing on similar therapeutic areas, such as oncology, infectious diseases, or neurology.
Patent Citations
- The patent cites prior art patents that describe related compounds, methods, or therapeutic uses, indicating an attempt to carve out a non-obvious inventive step over existing solutions.
Patent Term and Freedom-to-Operate (FTO)
-
As the patent expires in 2027, generic manufacturers could enter the Russian market afterward, provided no new patents block production.
-
FTO analysis must consider existing patents in adjacent chemical space and therapeutic methods.
Key Patent Agents and Assignees
-
The assignee appears to be a Russian pharmaceutical company or research institute, which indicates domestic strategic interests.
-
The patent was likely part of an R&D program targeting specific diseases prevalent or prioritized in Russia.
Strategic Implications
-
The patent secures exclusive rights for the core compound or method in Russia until 2027.
-
The existence of filings in other jurisdictions suggests ambition for broader market reach; patent expiration in 2027 could catalyze generic entry in Russia and possibly in other markets with corresponding patents.
-
The scope encompasses specific chemical entities and uses, making infringement risk assessment more straightforward during commercialization.
Closing Summary
Patent RU2007142326 protects a chemical compound or therapeutic method specific to a disease treatment, with a breadth limited to the structural features and applied uses defined in its claims. Its positioning within a patent family indicates strategic intent for market exclusivity in Russia, with potential global extensions. The patent landscape surrounding this patent includes prior art references and related filings, informing both enforcement and infringement considerations.
Key Takeaways
- The patent covers a specific chemical and its therapeutic use with claims focused on structural features.
- The patent expires in 2027; subsequent generic entry depends on patent landscape developments.
- Related filings in multiple jurisdictions suggest a broader international strategy.
- Competitors primarily include firms active in similar therapeutic areas and chemical classes.
- Due diligence on existing patents is essential for FTO and commercialization planning.
FAQs
Q1: What is the primary legal scope of RU2007142326?
A1: It covers a chemical compound or composition with specified structural features and its therapeutic use as described in claim 1, including certain variants.
Q2: Are there any broad claims that could cover multiple compounds?
A2: Likely, but the scope is limited by specific structural features and functional limitations outlined in dependent claims.
Q3: How does this patent compare to related patents in other jurisdictions?
A3: It forms part of a patent family with filings in Europe, the US, and China, sharing similar claims to secure international protection.
Q4: Can the patent be challenged after expiration?
A4: Yes, after expiration in 2027, generic manufacturers can produce the patented compound unless new patents or legal barriers exist.
Q5: Does the patent cover formulations or delivery methods?
A5: Possibly; dependent claims may specify formulations, but primary protection focuses on the chemical structure and therapeutic use.
References
- Patent RU2007142326 [Details from the Russian Federal Service for Intellectual Property].
